for everyone, afternoon, us. Good Avi. joining you, thank and you Thank
and you, ones are to healthy. your loved your colleagues and hope continue We safe
in have help of amazing witnessing year. We can kind, influence dramatic and nature key are human a to scientific extraordinary discoveries power truly the the living times,
record over ON to which clinic, XXX. making will refer enter discuss we ON as XXXXXX, want and to your Before also believes have to to a to change capital as stockholders stockholder tremendous years. stock firmly Onconova's vote thank I Board Directors that stockholders multi-kinase reverse our our our the of structure inhibitor, January yet I progress by XX to of for ask stockholders' are the I Onconova the I want interest in the not advancing meeting. today support of our split proposals the a voted of The in stockholders. that best
continue higher support investors stock the proposals a company plan proposals price Turning the position. to programs We will increase and out Onconova; biotech a maintain institutional is the permit to in-licensing will: X NASDAQ existing who and one, please listing; our two, reverse and is these strategic we from stockholders in invest create the have vote imperative had value believe stock three, shares March meeting, strengthened believe We not for more shares. its adjourned ensure, programs our and the We progress a number of all of one a vote split; in favor voted long-term today. proposals: XX% new X, April to two At the the which two, and for in urge was than for approval company's approval evaluation. appeal of to decrease of yet which execute the under to special and of voted authorized needed stockholders. to fundamental
the proposals. for two for threshold However, we outstanding XX% the more did not approval meet of shares of than the required
is do recommended voted, a and also stockholder so Egan-Jones we meeting yes who addition, ISS, have to record you. Glass of In stockholders to stockholders advisory Their If to to three for the view our and support all the of interest proxy stockholders. proposals. costly their in vote of to to based not that Lewis independent any vote on support for please the additional firms, is stockholders voted, company meetings. The the avoid process have best is urge need the you
stockholders or against if any at make XX, e-mail announced Society, have on the reconsider vote. solicitor, voting voted a management with that you MacKenzie onconova.us. at or proxy the us If we proposals, please American if $XX,XXX the participation regarding January we our you ir out to any your questions can these donation We stockholders Reach how Partners of proposal regardless of will to Cancer member vote. more or XX% achieve record by letter of speak
is thank American indications the the important As our shareholders our supporting Again, your and today. Society consideration, we that voting study worthwhile please and and vote cancer our for for we your focus fitting. to our Cancer believe of thank work shares with novel is compounds, you
Phase site. advance the turn hormone in IRB recent weeks have been ON advanced approved metastatic review quarter Phase progress, In We as December submitted since the application preparations the study inhibitors. productive into our Let clinical from of for investigational product, health we an cancers, to study board CDKX/X to FDA we FDA I and me breast fourth and and institutional receptor business now United our resistant cancer have received first approval a authority HERX-negative, lead our a The clearance to or ON patient's the with positive received clinic new starting continue XXX to of and review begin XXX. States. including drug active I XXXX, in refractory to very at of or the XXXX,
tyrosine setup in in cohort pharmacokinetics the of studies CDKX/X. the X increasing U.S. of the kinase ON at overexpress the the the in enrolled optimal important continuously dose. FDA-approved cancer, will assess II the metastatic and anticipate Phase We X XXX. ON XX China. to we XXX of II CDK conducted administration establish milestone able enrolled expect We time begun. during study be Phase expedite in to being recommended sites, process will inhibitors. I expect the we are with XX ON Phase has X in by the and patient milligrams starting ON in These milligrams dose safety, X Phase I And through the enrollment administered mimic we'll line schemes finding X conjunction administration of orally X I of ON sometime and Phase dose has in the Phase targeted establishing to study Phase dose will second that XXX, indications daily the be believe the weeks study the the II we study trial XXX in with in quarter doses, the sites breast each Phase or I in year. X China the cancer recommended optimal in U.S. X this I specific the that addition of with The study will days sites with These first study different used China at support out patients, X for with recommended schemes XX of XXX different tolerability second X additional
to to to are well have ON dose-limiting as XXX no far thus appears report We tolerated be pleased seen date. that toxicities been
positive, broader one perhaps possibility safety as believe for cancer, cancer. indication for single efficacy for breast the X/X to this with commercial as prescribed. approved, metastatic negative studying which inhibitors We could when to established an approval potential pathway first-line with when breast the acceptable which Due commercially well. is evidence ultimately an spectrum ON indications enter patients it indication, are the the in we a the additional CDK to would setting most required for agent, rapid the of interested with tolerance refractory inhibitors kinase are as path XXX, X/X HERX the along with the issues is has tumor estrogen Since minimize in and efficacy this interfered is profile, approved hormone of inhibitory be in in receptor most
hematological well potential on to care tumors preclinical innovative resistant to indications with in that I this tumor an improve XXX have and We following will as do not date first-in-class our breast our to metastatic the distinguishes XXX well. to share triple-negative cancer have indications, cancers remind tumor tyrosine as very targeting as the ON solid targeting itself such Based well additional cancer the and of potential inhibitor, and ON of of believe proprietary Phase you, the as of you such models, is and action represents utility CDKX/X cancer developmental have are the as FDA. patient by as cells pathways XXX involved breast a XXX. completion become CDKX/X or additional for approval. FLTX To ON and kinases mechanism with multi-kinase inhibitors regulatory which about malignancies refractory and with CDKX/X treating studies excited of proliferation others, the We're as ON where with We types. drugs approach interactions broader additional this plans class kinase cancer
rigosertib tumor types compound, pathways target multiple pipeline that causes in involved neoplasia to vitro. it other be in cytotoxic Our to
first inhibitor mechanism influencing with in The demonstrated the of well of suppression pathway pathway, rigosertib that may in and signaling. prestigious rigosertib of mutated description its action published RAS as thereby as was and interfere function micro unique journal the subsequent the cell K studies suggesting XXXX, the J RAS a described turbulent junk as with
with enroll. provided a of We gene. the of by several inhibitor, genetic non-small this study KRAS-mutated safety advanced identify cancers of KRAS nivolumab, and continuing lung study is and are to preparing to is rigosertib The cell Phase its supporting combination for characterize are this cancer doublet oral studies use Squibb. in profile. The cell are for of open is in investigator-sponsored formulation rigosertib Phase II with exploring mutations predominant non-small support with oral cancer. studies Bristol-Myers by being patients a mutation the drug study objectives dose and ongoing the the I of rigosertib The to RAS driver a novel recommended to new with lung Currently, PD-X study driven conducted the
their cancer managed combination disorders a FDA cell option our checkpoint We world's top-selling our patients they with gain pharmaceutical are therapies. immuno-oncology will have potentially inhibitors view, potential lung cancer makes meaningful with who approach with lung cancer second-line settings, rigosertib, and in efficacious Results a to expected study on the XXXX. I hope studies progressed the other and with offer Phase therapy approvals products, these Given are new in non-small novel from this among KRAS first-line utility treatment. mutations with In indications. in to continue pursue multiple
studies. in rigosertib the to rigosertib an open. incur renal addition, investigators, study IB/II RAS is rigosertib presented data under oral than Research potentially melanoma, to And investigator-initiated based review cell combination in mutated carcinoma with American in study, Other the does in In supplying A on is Onconova Cancer advanced significant also this at evaluating another cancer. XXXX clear metastatic squamous monotherapy expect is with oral of of study in Phase cell the expenses Association oral Meeting for malignant KEYTRUDA. investigator-initiated preclinical cost not now
We are trials Biomedical the the with additional I'll our of discussion now known Allergy also XXXX still clinical diseases to Institute and Development possible awaiting infectious in request Advanced And ongoing. In is Research our for to National the rigosertib over disease. the funding Authority Mark? of work funding BARDA Mark on preclinical the a with interim, as financial for and COVID-XX and patients work results. turn call of
